449 related articles for article (PubMed ID: 25844991)
1. Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths.
Rubin DM; Kreider AR; Matone M; Huang YS; Feudtner C; Ross ME; Localio AR
JAMA Pediatr; 2015 Apr; 169(4):e150285. PubMed ID: 25844991
[TBL] [Abstract][Full Text] [Related]
2. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth.
Bobo WV; Cooper WO; Stein CM; Olfson M; Graham D; Daugherty J; Fuchs DC; Ray WA
JAMA Psychiatry; 2013 Oct; 70(10):1067-75. PubMed ID: 23965896
[TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
[TBL] [Abstract][Full Text] [Related]
5. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
6. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
8. Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children.
Kreider AR; Matone M; Bellonci C; dosReis S; Feudtner C; Huang YS; Localio R; Rubin DM
J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):960-970.e2. PubMed ID: 25151419
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Use of Atypical Antipsychotics With Other Psychotropic Medication Classes and the Risk of Type 2 Diabetes Mellitus.
Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL
J Am Acad Child Adolesc Psychiatry; 2017 Aug; 56(8):642-651. PubMed ID: 28735693
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs.
Hartung DM; Zerzan J; Yamashita T; Tong S; Morden NE; Libby AM
Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):87-94. PubMed ID: 24142840
[TBL] [Abstract][Full Text] [Related]
11. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths.
Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL
JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Lin CY; Tsai GE; Wang HS; Wu YH; Chiou CC; Wu VY; Lane HY
J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
[TBL] [Abstract][Full Text] [Related]
13. Risk of manic switch associated with antidepressant therapy in pediatric bipolar depression.
Bhowmik D; Aparasu RR; Rajan SS; Sherer JT; Ochoa-Perez M; Chen H
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):551-61. PubMed ID: 25470655
[TBL] [Abstract][Full Text] [Related]
14. Neurological adverse events associated with antipsychotic treatment in children and adolescents.
Jerrell JM; Hwang TL; Livingston TS
J Child Neurol; 2008 Dec; 23(12):1392-9. PubMed ID: 18772491
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
16. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
[TBL] [Abstract][Full Text] [Related]
17. Increased Risk of Diabetes Among 6-24-Year-Olds Using Second Generation Antipsychotics.
Xing S; Lee TA
J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):782-791. PubMed ID: 28799787
[TBL] [Abstract][Full Text] [Related]
18. Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies.
Xing S; Kim S; Schumock GT; Touchette DR; Calip GS; Leow AD; Lee TA
Prim Care Companion CNS Disord; 2018 May; 20(3):. PubMed ID: 29873957
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic medication use among children and risk of diabetes mellitus.
Andrade SE; Lo JC; Roblin D; Fouayzi H; Connor DF; Penfold RB; Chandra M; Reed G; Gurwitz JH
Pediatrics; 2011 Dec; 128(6):1135-41. PubMed ID: 22106077
[TBL] [Abstract][Full Text] [Related]
20. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.
Guo Z; L'italien GJ; Jing Y; Baker RA; Forbes RA; Hebden T; Kim E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jul; 35(5):1326-32. PubMed ID: 21515328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
